Tibial Tunnel Widening in Anterior Cruciate Ligament (ACL) Reconstruction-Comparing Two Bioscrews

NCT ID: NCT01727739

Last Updated: 2019-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Widening of the single tibial tunnel following ACL surgery with quadrupled hamstrings autograft may contribute to failure of the graft and/or present technical challenges secondary to bone loss in a revision setting (Getelman, 1999). As such, efforts should be made to minimize the incidence and magnitude of tibial tunnel widening without sacrificing the biomechanical properties of the graft construct. The purpose of this investigation is to examine the tibial tunnel widening relationship between bioabsorbable interference screws composed of poly-L-lactic acid (PLLA) alone and composite bioabsorbable interference screws composed of poly-L-lactic acid embedded with beta tricalcium phosphate (PLLA+TCP) utilized as tibial fixation devices.

Specifically the study has the following objectives: 1) To quantify the extent of tibial tunnel enlargement at 3-, 6- and 12-months post ACL reconstruction with autogenous quadrupled hamstring graft; 2) To determine if the incorporation of beta tricalcium phosphate to the bioabsorbable interference screw alters the observed magnitude of tunnel widening; 3) To hypothesize mechanisms for any observed differences between tibial fixation devices; and 4) To correlate tibial tunnel widening with clinical outcome status. It is hypothesized that the PLLA+TCP bioabsorbable interference screw will not be associated with a reduction in tibial tunnel widening around the implant but rather between the implant and articular surface, compared to the PLLA alone screw. It is also hypothesized that there will be no effect of observed tunnel widening on clinical outcomes or graft failure rates.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ACL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PLLA bioscrew

poly-L-lactic acid bioscrew

Group Type ACTIVE_COMPARATOR

Linvatec PLLA

Intervention Type DEVICE

Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.

PLLA+TCP bioscrew

poly-l-lactic acid with beta tricalcium phosphate bioscrew

Group Type ACTIVE_COMPARATOR

Linvatec PLLA+TCP

Intervention Type DEVICE

Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linvatec PLLA+TCP

Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.

Intervention Type DEVICE

Linvatec PLLA

Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have a unilateral ACL rupture
* Patients must be between 18 and 45 years old

Exclusion Criteria

* Concomitant medial collateral, lateral collateral, or posterior collateral ligament tears
* Severe chondromalacia or severe meniscal tear
* Previous history of ipsilateral knee joint pathology, surgery, or trauma to that knee
* Unwillingness to be followed for 12 months post-operatively
* History of arthritis (osteoarthritis or rheumatoid)
* Pregnancy
* Psychiatric illness that precludes informed consent
* Unable to speak or read English/French
* Major medical illness (life expectancy less than 1 year or unacceptably high operative risk)
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Panam Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter MacDonald

Research Associate

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter B MacDonald, MD FRCS(C)

Role: PRINCIPAL_INVESTIGATOR

Pan Am Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pan Am Clinic

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2012:059

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Long Term Foundation Knee Study
NCT01274546 COMPLETED
Triathlon All-Polyethylene Tibia Outcomes Study
NCT04636190 ACTIVE_NOT_RECRUITING NA
Incrediwear ACL MCL Arthroscopic Surgery Recovery Study
NCT06240780 ENROLLING_BY_INVITATION NA